Quanterix Stock Plunges 9% After Its CEO Resigns For Another Healthcare Opportunity

The company kept its 2026 outlook and put its commercial chief in interim charge while the board searches for a permanent CEO.

Share
Quanterix Stock Plunges 9% After Its CEO Resigns For Another Healthcare Opportunity

Quanterix, which makes tools to measure proteins in blood and tissue, plunged 8.7% to $2.61 in Wednesday trading, as of 9:47 AM ET, losing $12 million in market value. The decline followed CEO Everett Cunningham's immediate resignation for another healthcare opportunity, according to an SEC filing.

Commercial Chief Takes Interim Charge

The interim CEO role went to Jim Gute, who serves as Chief Commercial Officer. Cunningham also left his positions as president and director; Quanterix reported no disagreements involving operations, finances, accounting or legal matters connected to his exit.

Quanterix kept its outlook for 2026 through the transition. The board hired an executive search firm and is considering both internal and external candidates for the permanent job.

Wednesday's decline put the stock on pace for its third drop of 7% or more this month. Quanterix's market value was about $123 million in Wednesday trading. At Tuesday's close, shares were down 55% for the year, compared with the S&P 500's 7% gain.

A Turnaround Still Losing Money

Gute joined in August during a management expansion tied to efforts to reorganize commercial teams. Quanterix named Dr. Yuri Fesko its first chief medical officer in September as it built out leadership for planned growth, particularly in diagnostics.

Third-quarter revenue reached $35 million, up 6.3% from the second quarter. Its $21.6 million net loss improved 35.6% from a year earlier.

Standard-accounting gross margin fell 0.9 percentage points from a year earlier to 38.6%. Adjusted gross margin rose 1.5 percentage points to 47.4%. Quanterix ended the quarter with $80.7 million in cash, cash equivalents, marketable securities and restricted cash.

Cunningham described the commercial overhaul in the earnings release issued Monday: “The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond,” he said in the earnings release.

Research Tools And Alzheimer's Testing

Quanterix sells instruments, test kits and software to researchers, alongside consumables, warranties and service contracts. Its Accelerator Laboratory in Bedford, Massachusetts, provides research services and clinical testing, including blood tests used to evaluate Alzheimer's disease and other neurological conditions.

The diagnostics business added partnerships with Sherman Abrams Lab in New York and TruPath in Mississippi. Beginning November 1, qualifying blood-based tests, including LucentAD Complete, became eligible for coverage for traditional Medicaid members and state employees in Florida when medical-necessity criteria are met.

Management's 2026 forecast calls for revenue of $142 million to $146 million and adjusted gross margin of 48% to 50%. Quanterix expects to finish the year with approximately $70 million in cash and no debt.

The permanent CEO search will proceed under the same financial outlook Quanterix retained through Cunningham's departure.

Sources

More on Quanterix

All Quanterix (QTRX) coverage →